IBDEI0DC ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6369,1,5,0)
 ;;=5^251.0
 ;;^UTILITY(U,$J,358.3,6369,2)
 ;;=^60589
 ;;^UTILITY(U,$J,358.3,6370,0)
 ;;=272.0^^44^512^4
 ;;^UTILITY(U,$J,358.3,6370,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6370,1,4,0)
 ;;=4^PURE HYPERCHOLESTEROLEM
 ;;^UTILITY(U,$J,358.3,6370,1,5,0)
 ;;=5^272.0
 ;;^UTILITY(U,$J,358.3,6370,2)
 ;;=^59973
 ;;^UTILITY(U,$J,358.3,6371,0)
 ;;=272.1^^44^512^5
 ;;^UTILITY(U,$J,358.3,6371,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6371,1,4,0)
 ;;=4^PURE HYPERGLYCERIDEMIA
 ;;^UTILITY(U,$J,358.3,6371,1,5,0)
 ;;=5^272.1
 ;;^UTILITY(U,$J,358.3,6371,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,6372,0)
 ;;=272.2^^44^512^3
 ;;^UTILITY(U,$J,358.3,6372,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6372,1,4,0)
 ;;=4^MIXED HYPERLIPIDEMIA
 ;;^UTILITY(U,$J,358.3,6372,1,5,0)
 ;;=5^272.2
 ;;^UTILITY(U,$J,358.3,6372,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,6373,0)
 ;;=272.4^^44^512^1
 ;;^UTILITY(U,$J,358.3,6373,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6373,1,4,0)
 ;;=4^HYPERLIPIDEMIA NEC/NOS
 ;;^UTILITY(U,$J,358.3,6373,1,5,0)
 ;;=5^272.4
 ;;^UTILITY(U,$J,358.3,6373,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,6374,0)
 ;;=272.6^^44^512^2
 ;;^UTILITY(U,$J,358.3,6374,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6374,1,4,0)
 ;;=4^LIPODYSTROPHY
 ;;^UTILITY(U,$J,358.3,6374,1,5,0)
 ;;=5^272.6
 ;;^UTILITY(U,$J,358.3,6374,2)
 ;;=^71106
 ;;^UTILITY(U,$J,358.3,6375,0)
 ;;=253.0^^44^513^1
 ;;^UTILITY(U,$J,358.3,6375,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6375,1,4,0)
 ;;=4^ACROMEGALY AND GIGANTISM
 ;;^UTILITY(U,$J,358.3,6375,1,5,0)
 ;;=5^253.0
 ;;^UTILITY(U,$J,358.3,6375,2)
 ;;=^2351
 ;;^UTILITY(U,$J,358.3,6376,0)
 ;;=255.0^^44^513^2
 ;;^UTILITY(U,$J,358.3,6376,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6376,1,4,0)
 ;;=4^CUSHING'S SYNDROME
 ;;^UTILITY(U,$J,358.3,6376,1,5,0)
 ;;=5^255.0
 ;;^UTILITY(U,$J,358.3,6376,2)
 ;;=^29802
 ;;^UTILITY(U,$J,358.3,6377,0)
 ;;=253.5^^44^513^3
 ;;^UTILITY(U,$J,358.3,6377,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6377,1,4,0)
 ;;=4^DIABETES INSIPIDUS
 ;;^UTILITY(U,$J,358.3,6377,1,5,0)
 ;;=5^253.5
 ;;^UTILITY(U,$J,358.3,6377,2)
 ;;=^33572
 ;;^UTILITY(U,$J,358.3,6378,0)
 ;;=253.8^^44^513^4
 ;;^UTILITY(U,$J,358.3,6378,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6378,1,4,0)
 ;;=4^EMPTY SELLA SYNDROME
 ;;^UTILITY(U,$J,358.3,6378,1,5,0)
 ;;=5^253.8
 ;;^UTILITY(U,$J,358.3,6378,2)
 ;;=^87533
 ;;^UTILITY(U,$J,358.3,6379,0)
 ;;=253.1^^44^513^5
 ;;^UTILITY(U,$J,358.3,6379,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6379,1,4,0)
 ;;=4^HYPERPROLACTINEMIA
 ;;^UTILITY(U,$J,358.3,6379,1,5,0)
 ;;=5^253.1
 ;;^UTILITY(U,$J,358.3,6379,2)
 ;;=^87260
 ;;^UTILITY(U,$J,358.3,6380,0)
 ;;=253.2^^44^513^6
 ;;^UTILITY(U,$J,358.3,6380,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6380,1,4,0)
 ;;=4^PANHYPOPITUITARISM
 ;;^UTILITY(U,$J,358.3,6380,1,5,0)
 ;;=5^253.2
 ;;^UTILITY(U,$J,358.3,6380,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,6381,0)
 ;;=227.3^^44^513^8
 ;;^UTILITY(U,$J,358.3,6381,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6381,1,4,0)
 ;;=4^PITUITARY TUMOR,BENIGN
 ;;^UTILITY(U,$J,358.3,6381,1,5,0)
 ;;=5^227.3
 ;;^UTILITY(U,$J,358.3,6381,2)
 ;;=^267690
 ;;^UTILITY(U,$J,358.3,6382,0)
 ;;=253.8^^44^513^9
 ;;^UTILITY(U,$J,358.3,6382,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6382,1,4,0)
 ;;=4^RATHKE'S CYST
 ;;^UTILITY(U,$J,358.3,6382,1,5,0)
 ;;=5^253.8
 ;;^UTILITY(U,$J,358.3,6382,2)
 ;;=^87533
 ;;^UTILITY(U,$J,358.3,6383,0)
 ;;=239.7^^44^513^7
 ;;^UTILITY(U,$J,358.3,6383,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,6383,1,4,0)
 ;;=4^PITUITARY TUMOR
 ;;^UTILITY(U,$J,358.3,6383,1,5,0)
 ;;=5^239.7
 ;;^UTILITY(U,$J,358.3,6383,2)
 ;;=^267785
